Koronis Pharmaceuticals
Koronis Pharmaceuticals is dedicated to developing innovative antiviral therapies, focusing on combating viral resistance in diseases such as HIV and hepatitis. The company employs advanced biotechnology tools and scientific research to create long-lasting and effective treatments, including novel mechanisms like Viral Decay Acceleration™ (VDA) and nucleoside analogs. Their mission is to improve treatment outcomes and broaden access to care worldwide through cutting-edge research and development.
Industries
Nr. of Employees
small (1-50)
Koronis Pharmaceuticals
6017 Snell Avenue, San Jose, CA 95123, United States
Products
Oral nucleoside prodrug candidate for inducing viral mutagenesis (lead candidate)
An orally administered prodrug converted in vivo to an active nucleoside analog that is incorporated by viral polymerases to increase mutation rates and reduce viral fitness.
Oral nucleoside prodrug candidate for inducing viral mutagenesis (lead candidate)
An orally administered prodrug converted in vivo to an active nucleoside analog that is incorporated by viral polymerases to increase mutation rates and reduce viral fitness.
Services
Design and conduct of Phase I and Phase II clinical studies including dose-escalation, randomized placebo-controlled, and open-label multicenter trials to evaluate safety, tolerability and pharmacokinetics.
Development and execution of cell-based antiviral assays, mutation-detection assays, and genomic analysis methods to evaluate candidate compounds in vitro.
Sequencing and bioinformatic analysis to monitor viral population diversity, measure treatment-induced mutation spectra, and support genotype/phenotype correlation studies.
Design and conduct of Phase I and Phase II clinical studies including dose-escalation, randomized placebo-controlled, and open-label multicenter trials to evaluate safety, tolerability and pharmacokinetics.
Development and execution of cell-based antiviral assays, mutation-detection assays, and genomic analysis methods to evaluate candidate compounds in vitro.
Sequencing and bioinformatic analysis to monitor viral population diversity, measure treatment-induced mutation spectra, and support genotype/phenotype correlation studies.
Expertise Areas
- Antiviral drug discovery
- Nucleoside analog design and prodrug chemistry
- Virology and viral evolution
- Clinical trial management (Phase I/II)
Key Technologies
- Viral lethal mutagenesis / error-catastrophe approach
- Nucleoside analogs and prodrug platforms
- Viral polymerase substrate engineering
- Cell-based viral replication assays